AnaptysBio Inc. is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases. It advances antibody-based drug candidates that modulate immune pathways, including rosnilimab, a PD-1 agonist and pathogenic T cell depleter studied in rheumatoid arthritis; ANB033, a CD122 antagonist in trials for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator; and ANB032, a BTLA agonist for atopic dermatitis. The company has discovered and out-licensed therapeutic antibodies through financial collaborations, such as Jemperli (dostarlimab-gxly), a PD-1 antagonist to GSK for oncology indications, and imsidolimab, an IL-36 receptor antagonist to Vanda Pharmaceuticals for generalized pustular psoriasis. These partnerships provide eligibility for milestone payments and royalties. AnaptysBio Inc. maintains biopharma operations centered on internal clinical programs alongside its royalty-generating assets. Headquartered in San Diego, California, since 2005, it plays a key role in the immunology sector by targeting immune cell modulation to address unmet needs in autoimmune conditions.